

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	nation	
1. Given Name (Fi Masahiro	rst Name)	2. Surname (Last Name) Takada	3. Date 25-March-2020
4. Are you the cor	responding author?	✓ Yes No	
5. Manuscript Title Neoadjuvant tre	e atment for HER2-posit	ive breast cancer	
6. Manuscript Ider	ntifying Number (if you k	now it)	
Section 2.	The Work Under C	Consideration for Publication	
Did you or your ins	stitution at any time reco	eive payment or services from a third party	(government, commercial, private foundation, etc.) for

any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? <u>(</u>]: _+ . c :..... 🖌 No . +h ۸. ~1.

Are there any relevant conflicts of inte	erest?	Yes [√

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.

Are there any relevant conflicts of interest?	Ves	No
Are there any relevant connicts of interest:	162	

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Chugai				\checkmark	Honorarium	
AstraZeneca				\checkmark	Honorarium	
Pfizer				\checkmark	Honorarium	
Eli-lilly				\checkmark	Honorarium	
Eisai				\checkmark	Honorarium	
Daiichi Sankyo				\checkmark	Honorarium	
Kyowa-Kirin				\checkmark	Honorarium	
Eisai	\checkmark					



Name of Entity	Grant?	Personal Fees ?	Non-Financial Support?	Other?	Comments	
Nipponkayaku	\checkmark					
Takeda				\checkmark	Honorarium	
Nipponkayaku				\checkmark	Honorarium	

Section 4.

Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes 🖌 No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Takada reports other from Chugai, other from AstraZeneca, other from Pfizer, other from Eli-lilly, other from Eisai, other from Daiichi Sankyo, other from Kyowa-Kirin, grants from Eisai, grants from Nipponkayaku, other from Takeda, other from Nipponkayaku, outside the submitted work; .



Evaluation and Feedback

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	ation			
1. Given Name (First Name) Masakazu		2. Surname (La Toi	ast Name)	3. Date 19-March-2020	
4. Are you the corr	responding author?	Yes	No		
5. Manuscript Title	2				
6. Manuscript Ider	ntifying Number (if you kr	ow it)			
Section 2.	The Work Under Co	onsideration	for Publicati	on	
any aspect of the s statistical analysis,	ubmitted work (including	but not limited t			nt, commercial, private foundation, etc.) for dy design, manuscript preparation,

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?		No
Are there any relevant connicts of interest:	I I I I I I I I I I I I I I I I I I I	

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Chugai	\checkmark	\checkmark			Research grant, Lecture honoraria	
Takeda	\checkmark	\checkmark			Research grant, Lecture honoraria	
Pfizer	\checkmark	\checkmark			Research grant, Lecture honoraria	
Kyowa-Hakko-Kirin	\checkmark	\checkmark		\checkmark	Research grant, Lecture honoraria, Advisory role for a drug development	
Taiho	\checkmark	\checkmark			Research grant, Lecture honoraria	
JBCRG association	\checkmark				Research grant	
Eisai	\checkmark	\checkmark			Research grant, Lecture honoraria	



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Daiichi-Sankyo	\checkmark	\checkmark		\checkmark	Research grant, Lecture honoraria, Advisory role for a drug development
Astra Zeneca	\checkmark	\checkmark			Research grant, Lecture honoraria
Eli Lilly		\checkmark			Lecture Honoraria
MSD		\checkmark			Lecture Honoraria
Genomic Health		\checkmark			Lecture Honoraria
Novartis		\checkmark			Lecture Honoraria
Konica Minolta		\checkmark		\checkmark	Honoraria for an advisory meeting
Astellas	\checkmark				Research grant
BMS				\checkmark	Honoraria for an advisory meeting
Shimadzu	\checkmark	\checkmark			Research grant, Lecture Honoraria
Yakult		\checkmark			Lecture Honoraria
Nippon Kayaku	\checkmark	\checkmark			Research Fund and Honoraria for lecture
AFI technologies	\checkmark				Research grant
Athenex Oncology				\checkmark	An advisory role

Section 4.

Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?	Yes	🖌 No
--	-----	------



Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

✓ Yes, the following relationships/conditions/circumstances are present (explain below):

No other relationships/conditions/circumstances that present a potential conflict of interest

Board of directors;

JBCRG association, Organisation for Oncology and Translational Research, Kyoto Breast cancer Research Network

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Toi reports grants and personal fees from Chugai, grants and personal fees from Takeda, grants and personal fees from Pfizer, grants, personal fees and other from Kyowa-Hakko-Kirin, grants and personal fees from Taiho, grants from JBCRG association, grants and personal fees from Eisai, grants, personal fees and other from Daiichi-Sankyo, grants and personal fees from Astra Zeneca, personal fees from Eli Lilly, personal fees from MSD, personal fees from Genomic Health, personal fees from Novartis, personal fees and other from Konica Minolta, grants from Astellas, other from BMS, grants and personal fees from Shimadzu, personal fees from Yakult, grants and personal fees from Nippon Kayaku, grants from AFI technologies, other from Athenex Oncology, outside the submitted work; and Board of directors; JBCRG association, Organisation for Oncology and Translational Research, Kyoto Breast cancer Research Network.

Evaluation and Feedback

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.